February 11, 2022 -- CytoReason has extended its collaboration agreement with Pfizer to investigate challenging biological questions that potentially inform the development of new therapies for the benefit of patients.
Since launching the collaboration in 2019, Pfizer has used CytoReason's models in Pfizer's research to enhance the understanding of the immune system in pursuit of developing innovative drugs. CytoReason's platform has provided Pfizer with multiple insights in a number of R&D programs across over 20 diseases, according to CytoReason.
No further financial details were disclosed.
CytoReason's multidisciplinary team of 65 leading biologists, bioinformaticians, and data engineers has developed a technology that enables pharma and biotech companies to speed drug R&D and bring novel therapies to the patients who most need them.